Trial Profile
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Cisplatin; Gemcitabine; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 30 Mar 2023 Status changed from active, no longer recruiting to completed.
- 14 Sep 2022 Planned End Date changed from 1 Jul 2022 to 1 Mar 2023.
- 31 Aug 2021 Planned primary completion date changed from 1 Jul 2021 to 1 Jul 2022.